Gilead to acquire CGI

FOSTER CITY, Calif. Gilead Sciences plans to acquire a development-stage pharmaceutical company for up to $120 million, Gilead said Friday.

Privately held CGI Pharmaceuticals has developed a library of drugs that have potential to treat inflammatory diseases such as rheumatoid arthritis. The majority of the $120 million will be an upfront payment, and the remaining will be based on clinical development progress, Gilead said.

“The acquisition of CGI represents a unique opportunity to expand our research efforts in an interesting and promising area of drug discovery,” Gilead EVP research and development and chief scientific officer Norbert Bischofberger said.

Login or Register to post a comment.